157893-14-6

Basic information

• Product Name: 3-BROMO-5-METHOXYBENZOIC ACID
• Synonyms: 5-BROMO-3-METHOXYBENZOIC ACID;3-BROMO-5-METHOXYBENZOIC ACID;3-Bromo-5-methoxybenzoic acid 99%;3-Bromo-5-carboxyanisole;3-Bromo-5-carboxyanisole, 5-Bromo-m-anisic acid
• CAS NO: 157893-14-6
• Molecular Formula: C₈H₇BrO₃
• Molecular Weight: 231.04
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 157893-14-6.mol
• Article Data: 16

Chemical Properties

• Melting Point: 190-191 °C(Solv: ethanol (64-17-5))
• Boiling Point: 338.8 °C at 760 mmHg
• Flash Point: 158.7 °C
• Appearance: /
• Density: 1.625 g/cm³
• Vapor Pressure: 3.74E-05mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: Room temperature.
• PKA: 3.69±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-5-METHOXYBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-METHOXYBENZOIC ACID(157893-14-6)
• EPA Substance Registry System: 3-BROMO-5-METHOXYBENZOIC ACID(157893-14-6)

Safety Data

• Hazardous Substances Data: 157893-14-6(Hazardous Substances Data)

Usage

General Description

3-Bromo-5-methoxybenzoic acid is a chemical compound with the molecular formula C8H7BrO3. It is an organic compound with a benzene ring substituted with a bromine atom and a methoxy group. 3-Bromo-5-methoxybenzoic acid is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in the production of various organic compounds. The presence of the bromine atom and the methoxy group in its structure makes 3-Bromo-5-methoxybenzoic acid a valuable reagent in organic synthesis for the formation of more complex molecules. Overall, this compound has a range of applications in the pharmaceutical, chemical, and agricultural industries.

InChI:InChI=1/C8H7BrO3/c1-12-7-3-5(8(10)11)2-6(9)4-7/h2-4H,1H3,(H,10,11)

Upstream product

• 864293-44-7 2-amino-5-bromo-3-methoxy benzoic acid 
• 3177-80-8 2-amino-3-methoxybenzoic acid 
• 618-58-6 3,5-dibromobenzoic acid 
• 124-41-4 sodium methylate 
• 6303-21-5 hypophosphorous acid 
• 867366-91-4 3-bromo-5-methoxybenzonitrile 
• 29578-83-4 3-bromo-5-methoxytoluene 
• 140472-69-1 3-bromo-5-hydroxy-benzoic acid 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 262450-64-6 (3-bromo-5-methoxyphenyl)methanol 
• 262450-65-7 3-bromo-5-methoxybenzaldehyde 
• 262450-67-9 2-(3-bromo-5-methoxyphenyl)ethylamine 
• 262450-76-0 1-(2-benzyloxybenzyl)-8-bromo-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline 
• 262450-69-1 N-(3-bromo-5-methoxyphenethyl)-2-benzyloxyphenylacetamide 
• 262450-70-4 1-(2-benzyloxybenzyl)-6-bromo-8-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline 
• 262450-71-5 1-(2-benzyloxybenzyl)-6-bromo-8-methoxy-2-ethyl-1,2,3,4-tetrahydroisoquinoline 
• 262450-77-1 1-(2-benzyloxybenzyl)-8-bromo-6-methoxy-2-ethyl-1,2,3,4-tetrahydroisoquinoline 
• 262450-78-2 1-(2-benzyloxybenzyl)-8-bromo-6-methoxy-2-propyl-1,2,3,4-tetrahydroisoquinoline 
• 1041114-55-9 3-methoxy-5-(6-methoxy-2-naphthyl)benzoic acid 
• 1261582-04-0 3-bromo-5-methoxybenzoyl chloride 
• 56709-70-7 3-bromo-5-methoxy-benzoic acid methyl ester 
• 1509919-85-0 3-(3-bromo-5-methoxybenzamido)furo[2,3-b]pyridine-2-carboxamide 

Relevant articles and documents

Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation

We synthesized six novel BBR derivatives that were designed to avoid metabolic activation via ipso-substitution and evaluated for their degree of toxicity and hURAT1 inhibition. It was found that all of the derivatives demonstrate lower cytotoxicity in mouse hepatocytes and lower levels of metabolic activation than BBR, while maintaining their inhibitory activity toward the uric acid transporter. We propose that these derivatives could serve as effective uricosuric agents that have much better safety profiles than BBR.

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

COVALENT INHIBITORS OF KRAS G12C

Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.